

7.5.3 bioMérieux historical share price performance

Period	High (in euros)	Low (in euros)	Closing (in euros)
2022	125.55	79.66	97.92
2021	133.20	88.86	124.90
2020	144.8	75.00	115.40
2019	83.15	53.10	79.35
2018	83.15	53.10	57.50

Source: Thomson Reuters Eikon, price recalculated after 3-for-1 stock split.

7.6 Dividend policy

The distribution policy is decided in light of the yearly analysis of the Company's profits, its financial position and other factors that the Board of Directors considers relevant.

Dividends that remain unclaimed five years after their payment date are time-barred and remitted to the French government.

At the Annual General Meeting to be held on May 23, 2023, the Board of Directors will recommend a dividend of €0.85 per share, representing a total of €100.6 million to be paid on June 8, 2023.

The table below presents the dividends (in euros) paid by the Company for each of the past three fiscal years.

Fiscal year ended	Dividend distributed (in euros)*	Dividend per share (in euros)*
12/31/2021	101,702,602.85	0.85
12/31/2020	73,383,956.40	0.62
12/31/2019	22,488,631.80	0.19

* The Company did not receive any dividends on treasury shares held on the ex-dividend date. The corresponding dividend amount was allocated to "retained earnings." Individuals domiciled in France for tax purposes benefit from a tax deduction on the annual dividend in accordance with paragraph 2 of Article 158.3 of the French Tax Code (Code général des impôts).

7.7 Special report on free share grants and stock options

This report was prepared in accordance with the provisions of Articles L. 225-184 and L. 225-197-4 of the French Commercial Code. The Company does not currently have any stock option plans. No stock options were granted to corporate officers or employees by the Company or Group companies in 2022. At the date of this report, no stock options are exercisable.

For the fiscal year ended December 31, 2022, the Board of Directors granted 272,218 free shares under free share grant plans set up by the Board – after consulting with the Human Resources, Compensation and CSR Committee – pursuant to the authority granted to it by the Combined General Meeting of May 20, 2021.

In this connection, the Company allocated free shares to a corporate officer in respect of his office held in the Company. The Board of Directors thus allocated 7,875 free shares to Pierre Boulud, Chief Operating Officer (EC 220830 A&B plan).

The table below details the free shares granted at the end of the 2022 fiscal year:

Grant date	Number of shares granted	Share price (in euros)
08/30/2022	272,218	96.68

The table below shows the number of free shares granted and not fully vested at the end of 2022:

Grant date	Share price (in euros)	Number of shares granted	Beneficiary category
08/30/2022	96.68	36,000	7 members of the Executive Committee, of which 1 corporate officer
Total EC 220830 plan (A&B)			
08/30/2022	96.68	236,218	456 employees
Total TPGL 220830 plan (A&B)			
GRAND TOTAL		272,218	463

Vesting period

In the 2022 free share grant plans, a three-year vesting period applies from the date of the decision to grant the shares before the beneficiary becomes the owner of the shares granted.

Eligibility and performance conditions

During the fiscal year, the Board of Directors decided, at the recommendation of the Human Resources, Compensation and CSR Committee, to grant free shares that are fully vested, (i) subject to a continuous employment condition and (ii) subject to performance conditions.

Delivery of shares

At the end of the vesting period and provided that the vesting conditions and criteria set by the Board of Directors are met, the Company will transfer to the beneficiary the number of free shares granted by the Board of Directors.

Lock-up period

Free share grant plans for 2022 have no lock-up period.

Beneficiaries' rights

If the shares are not transferable, like any other shareholder, the beneficiaries of vested shares are entitled to exercise all other rights attached to such shares during the lock-up period, including:

- pre-emptive subscription rights;
- right to information;
- right to attend Annual General Meetings;
- voting rights;
- right to dividends and, if applicable, distributed reserves.

History of free share grants (Table 10)

The table below summarizes, at December 31, 2022, all the terms and conditions of the free share grants and the performance share grants, subject to the fulfillment of the presence conditions and, for certain grants, the performance criteria laid down by the Company's Board of Directors:

Date of Annual General Meeting	Name of plan	Date of Board meeting	Total number of free shares granted	Number of beneficiaries	Of which a corporate officer	Acquisition date of the shares	End date of the lock-up period	Cumulative number of forfeited or lapsed shares	Free shares granted during the fiscal year	Free shares remaining at the end of the fiscal year
May 20, 2021	EC 220830 and TPGL 220830 Plan	August 30, 2022	272,218	463	1	August 30, 2025	August 30, 2025	0	0	272,218
May 20, 2021	2021 EC and TPGL Plan	August 31, 2021	175,315	366	1	August 31, 2024	August 31, 2024	13,133	0	162,182
June 30, 2020	2020 EC Plan	September 1, 2020	29,000	8	1	September 1, 2023	September 1, 2023	2,000	0	27,000
June 30, 2020	2020 TPGL Plan	September 1, 2020	97,103	335	0	September 1, 2023	September 1, 2023	15,470	0	81,633
May 17, 2018	Invisible Sentinel Plan ^(a)	February 26, 2019	22,300	10	0	February 26, 2022	February 26, 2022	22,300	0	0
May 17, 2018	2019 EXCOM Plan	February 26, 2019	80,510	12	0	February 26, 2022	February 26, 2022	27,469	53,041	0
May 17, 2018	2019 BioFire Plan	February 26, 2019	26,250	7	0	February 26, 2022	February 26, 2022	15,000	11,250	0
May 17, 2018	2019 Global Leader/TP Plan	September 3, 2019	137,129	357	0	September 3, 2022	September 3, 2022	18,179	118,950	0
May 17, 2018	Global Leader Plan ^(b)	May 17, 2018	15,000	1	0	May 17, 2022	May 17, 2022	0	15,000	0
May 17, 2018	2018 EXCOM Plan	May 17, 2018	20,000	1	0	May 17, 2022	May 17, 2022	0	20,000	0

(a) No shares will be granted under this plan as the performance criteria were not met.

(b) Free shares granted subject to performance criteria.

Performance share grants to employees during the 2022 fiscal year

In fiscal year 2022, the 10 non-corporate officer employees who were granted the most performance shares received a total of 59,537 shares.